GLP1R and glaucoma: A recent association between exposure to GLP-1R agonists and a reduced risk of glaucoma makes it even more justified to consider the neuroprotective potential of GLP-1R agonists, particularly semaglutide, in anti-glaucomatous treatment strategies.